US Edition
Trinity Biotech unveils next-gen AI-powered CGM biosensor
Summary by Drug Delivery Business
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Trinity Biotech unveils next-gen AI-powered CGM biosensor
The CGM+ worn on the back of the arm. [Image courtesy of Trinity Biotech]Trinity Biotech (Nasdaq:TRIB) announced today that it unveiled its new flagship continuous glucose monitor (CGM) biosensor system. CGM+, a next-gen wearable biosensor, aims to take on the growing AI wearables market. The Dublin, Ireland-based company said it has the system in the later stages of device development. The new AI-native CGM combines multi-sensor data with real-…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
